2013 Annual Report

Conquering Thoracic Cancers Worldwide

IASLC in 2013

Introduction

The International Association for the Study of Lung Cancer (IASLC) celebrates in 2014 its 40 years anniversary. Much has been accomplished over that time as described in the recently published special IASLC Progress in Lung Cancer 40-years Anniversary Monograph. However, lung cancer remains to be a significant health problem and a challenge to conquer. IASLC is committed to the challenges to ensure that optimal care of patients with thoracic malignancies is ensured all over the world. Members, volunteers, and staff of the IASLC have worked diligently to accomplish the goals of the strategic plan and fulfill the mission of the society. The purpose of this report is to highlight the progress over the past year and to set the tone for the upcoming year.

It is our hope that this Annual IASLC Report will demonstrate the many activities within IASLC and the progress made.

Fred R. Hirsch, MD, PhD Tony S. Mok, MD

Chief Executive Officer President

1

IASLC in 2013

Table of Contents

Introduction 1

Organization Structure 3

Membership 6

Fellowships 8

Educational Activities 10

Publications 12

Awards 16

Meetings 19

Strategic Plan 22

Advocacy Partners and Sponsors 26

Future Plans 27

2

IASLC in 2013

Organization Structure

IASLC Officers

Position 2011-2013 2013-2015

President Peter Goldstraw Tony Mok

Immediate Past President David Gandara Peter Goldstraw

President Elect Tony Mok David Carbone

Treasurer Fred R. Hirsch David Gandara

Chief Executive Officer Paul A. Bunn, Jr. Fred R. Hirsch

IASLC Directors

2009-2013 2011-2015 2013-2017

Hak Choy Silvia Novello Francoise Mornex

Karen Kelly Carolyn Dresler Keith Kerr

David Carbone Christian Manegold William Travis

Johan Vansteenkiste Tetsuya Mitsudomi Solange Peters

Dominique Grunenwald Kazuhiko Nagokawa Laurie Gaspar

Rolf Stahel Alex Adjei Pasi Janne

Hisao Asamura Sumitra Thongprasert Yuichiro Ohe

Keunchil Park Yi-Long Wu

IASLC Staff

Position

Chief Executive Officer Fred R. Hirsch

Chief Operating and Financial Officer John Wetherington

Director of Communications Vacant Director of Education, Corporate

Relations and Governance Pia Hirsch

Director of Membership Kristin Richeimer

Membership Coordinator Pamela Freelon

CME/Education Coordinator Paul Silvey

Special Projects Manager Murry Wynes

Asian Office Vengie Lau

JTO Editorial Manager Mary Sharkey

3

IASLC in 2013

IASLC Committees

Committee Chair Past-Chair

Awards Tony Mok Peter Goldstraw

Bylaws Vacant George Simon

Career Development Martin Edelman

Communication Anne Tsao Heather Wakelee

Education Suresh Ramalingam Primo Lara

Advanced Radiation Therapy Laurie Gaspar Francoise Mornex Hak Choy

Continuing Medical Education Ramaswamy Govindan

Ethics Eduardo Richardet Kwun Fong

Fellowship Benjamin Besse Phillip Mack

Finance David Gandara Fred R. Hirsch

Membership Surish Senan Nise Yamaguchi

Nominating David Gandara Kathy Albain

Nurses & Allied Health Professional Patricia Hollen

Pathology Andrew Nicholson Ming Tsao

Patient Advocacy Glenda Colburn

Prevention & Early Detection Nir Peled John Field

Publication Harvey Pass Glenwood Goss

Staging Ramon Rami-Porta Peter Goldstraw

Tobacco Control/Smoking Cessation Michael Cummings Carolyn Dresler

Asia Pacific Lung Cancer Sumitra Thongprasert

Task Forces

Task Force Chair Industry Rolf Stahel

Patient Education Silvia Novello

4

IASLC in 2013

Members – The IASLC brings together a broad array of global stakeholders including clinical practitioners, scientists, patient advocates, and industry executives; all dedicated to prevention, screening, imaging, diagnosis, and treatment of thoracic malignancies. Members provide their expertise in order to collaborate and share the most timely and relevant scientific and clinical information to the IASLC for distribution around the world. This commitment allows IASLC to be the premier global source of information on thoracic malignancies. Members devote their time to lead IASLC sponsored meetings and conferences, take active roles in various committees, provide presentations on cutting-edge basic, translational, and clinical science, and establish robust interactions to further the IASLC mission.

Board of Directors –The IASLC board of directors provide a wealth of clinical and scientific expertise, along with a rich experience with other societies and institutional leadership. IASLC board members promote the ongoing growth in programs and support provided by the IASLC through their strategic guidance as well as operational and financial oversight.

Headquarters Staff – Under the leadership of the CEO, the staff implements the diverse education, membership, communication, outreach, fundraising and scientific programs of the organization. From facilitating numerous conferences to producing webinars, publishing books and digital applications, the staff timely distributes the best and most current information to thousands of stakeholders around the globe. The staff distributes these regular communications with the members and stakeholders by maintaining up-to-date contact information. The staff is accountable for the financial management of the IASLC’s operations and assets as well as responsible for obtaining sponsorships for various activities and events. The staff supports, gives expert advice, and helps implement the decisions of the committees and the board.

5

IASLC in 2013

Membership

2013 was Another Record Year for Membership IASLC membership has experienced 29% growth between 2011 and 2013, ending the year with nearly 3,800 members, a record for IASLC. The strongest growth rate is in the Allied Professionals (190%), Developing Countries (106% increase), and Complimentary Fellows memberships (85% increase). This overall growth in the number of IASLC members has been achieved through acquiring new members following IASLC meetings and online educational webinars, as well as increased member retention efforts. The IASLC’s member retention rate has increased from 81% in 2011 to 85% in 2013.

Attracting Members from the Entire Multi-Disciplinary Team IASLC has established a goal of educating the entire team of providers for lung cancer patients. To further that goal the Membership Committee, led by 2011-2013 Chair Nise Yamaguchi (Brazil) and staff, have updated member communications to include language specifying that IASLC membership is valuable to anyone who is involved in lung cancer around the world. IASLC is actively seeking to increase its membership among pathologists, diagnostic radiologists, and basic scientists. The series of Advanced Radiation Technology (ART) Webinars provided a unique vehicle to attract new members in this specialty, and in fact, led to a 100% increase in Diagnostic Radiology members from 2012 to 2013. Suresh Senan (Netherlands) has assumed the role of Membership Committee Chair in 2013, and will bring a unique perspective as a radiation oncologist. In addition, IASLC has made special efforts to attract new members in the Allied Health Professional category, such as Nurses, Advocates, Pharmacists, Statisticians, and others. The numbers of Nurses and other Allied Health Professionals members have tripled since 2011.

6

IASLC in 2013

Invite-a-Fellow Promotion In late 2012, IASLC adjusted the fellow membership to allow more students and trainees from any discipline (including allied health professions) and in 2013, IASLC introduced an online campaign for existing members to invite a fellow to take advantage of the complimentary fellow membership and join IASLC. These efforts resulted in a 70% increase in Fellow membership from 2012 to 2013, compared to only a 10% increase in the previous annual cycle.

Operational and Technology Upgrades Improve Efficiency With IASLC’s rapidly growing membership, it was important for the IASLC membership staff to evaluate technology and make systematic improvements to the online registration systems and member database to increase efficiency and reduce long term costs for the organization. The new online registration system and database have helped improve retention rates due to system efficiency and increased renewal contacts and efforts. It has led to improved demographic collection to include types of thoracic cancers treated and practice types. These upgrades have also allowed us to improve integration with JTO publisher for easier member setup of online JTO subscription and streamline conflict of interest process by using online submission.

IASLC Membership – Looking Ahead In 2014, a strong emphasis will be placed on improving the IASLC member experience and we hope to make it even easier for members to engage with IASLC. IASLC will continue with the annual membership survey, introduced in 2013, and will use the information to help guide member benefit offers and other initiatives. IASLC will strive to continue the impressive growth experienced over the last several years. The organization has several introductory offers in place with partner organizations, such as Japan Lung Cancer Society, Pulmonary Pathology Society, Brazilian Group of Thoracic Oncology, and the International Thoracic Oncology Nurses Forum and National Lung Cancer Nurses Forum (UK). In early 2014, IASLC will launch its new online, searchable membership directory and will provide increased opportunities for online education

7

IASLC in 2013

Fellowships

IASLC continued its support in 2013 for young investigators in order to reward scientific excellence and to encourage innovative research in lung cancer prevention as well as clinical and translational medicine worldwide. Global submissions to our fellowship had many excellent candidates who were evaluated by a Scientific Review Panel for their merit, innovation and potential impact on the future management and treatment of lung cancer. In 2013 there were 4 fellowships (3 were 2-year awards, and 1 was a 1-year award) given to outstanding young investigators through IASLC. Additionally 2 specially-designated fellowships were awarded. One was through a joint collaboration with Lung Cancer Foundation of America (LCFA) for a 2-year award and the other was a joint collaboration with Boehringer Ingelheim China that enabled a fellow to come to the United States to perform a 1-year research project.

Recipient Mentor Institution Project Grantor / Award Period

Peter Choi

Matthew Myerson

Dana-Farber Cancer Institute, Boston, USA.

Functional role of RBM10 in lung cancer, and potential interactions between RBM10 and established oncogenes.

IASLC/ 2013-2015

Narenda Wajapeyee

Yale University, New Haven, USA.

Targeting metabolic drivers of lung cancer.

IASLC/ 2013-2015

Daniela Morales-Espinosa

Rafael Rosell

Catalan Institute of Oncology, Barcelona, Spain.

The re-replication pathway and its involvement in growth dependency and inhibition by use of specific tyrosine kinase inhibitors (TKIs).

IASLC/ 2013-2015

Patrick Forde

Julie Brahmer

Patrick Forde, Johns Hopkins University, Baltimore, USA.

How an anti-PD-1 drug called nivolumab, benefits patients with non-small cell lung cancer.

IASLC/ 2013-2014

8

IASLC in 2013

Recipient Mentor Institution Project Grantor / Award Period

Daniel Costa

Beth Israel Deaconess Medical Center Boston, USA.

Studying why EGFR exon 20 insertion mutations are different than other EGFR mutations and how to develop novel treatment strategies for tumors that harbor these changes.

IASLC and Lung Cancer Foundation of America / 2013-2015

Lu-Lu Yang

Pasi Janne Dana-Farber Cancer Institute Boston, USA

Effects of combination treatment with selumetinib and pemetrexed in KRAS mutant NSCLC, and mechanisms of acquired resistance.

IASLC and Boehringer Ingelheim China / 2013-2014

All awardees were appreciative of the awards and recognized the benefits the lung cancer community will obtain from their research. Dr. Choi remarked, “I was really surprised and very excited to receive this award”. “I hope this project will shed some light on how and why this gene is involved in lung cancer.” Dr. Wajapeyee noted, “If we can identify an effective method of treatment, it will allow us to help treat and save lives of a large number of cancer patients.” Dr. Morales-Espinosa thanks the IASLC and commented “This opportunity is really important for junior oncologists.” Dr. Forde expressed “This is a great opportunity for me and our project.” “It will allow me protected research time.” Dr. Costa states “My research team and I are very grateful and with it this project can move forward.’ “We want to try to improve care of patients by characterizing their tumor mutations in a systematic fashion. This could help doctors know if and when they should treat patients with certain drugs and could also lay groundwork for clinical trials in a patient population.”

9

IASLC in 2013

Educational Activities

The IASLC has expanded its number of Continuing Medical Education (CME) accredited programs in 2013 after becoming a CME provider accredited by the Accreditation Council of Continuing Medical Education (ACCME) in December of 2012. A number of the programs in 2013 were webinars.

2013 Webinars

Title Presenter

Advanced Radiation Therapy Committee Session 1: Q&A – Non-CME Billy Loo and Suresh Senan

Advanced Radiation Therapy Committee Session 2: Motion Control – Non-CME

Jan Jakob Sonke and Brian Kavanagh

Advanced Radiation Therapy Committee Session 3: Treatment Planning – Non-CME

Robert Timmerman and Timothy Solbert

Advanced Radiation Therapy Committee Session 4: SBRT Delivery – Non-CME David Jaffray and Jeffrey Bradley

Understanding Immunotherapeutic Approaches in Non-small Cell Lung Cancer –CME Activity

Dmitry Gabrilovich, David Carbone, and Johan Vansteenkiste

Molecular profiling and personalized medicine for patients with lung cancer - CME Activity David Gandara

The relevance of histological diagnosis in making treatment decisions - CME Activity Giorgio Scagliotti

Making NSCLC a chronic disease: reality or dream? - CME Activity Tony Mok

New targets for lung cancer - CME Activity Suresh Ramalingam

CAP IASLC AMP Molecular Testing Guidelines – Non-CME

Molecular profiling and personalized medicine for patients with lung cancer – Non-CME Fabrice Barlesi

The relevance of histological diagnosis in making treatment decisions – Non-CME Giorgio Scagliotti

New targets for lung cancer – Non-CME Tim Benopal

10

IASLC in 2013

The IASLC will continue in 2014 with more educational activities. An entire grand rounds webinar series is planned in 2014 and will include 14 monthly presentations. Ramaswamy Govindan, the chair of the Continuing Medical Education subcommittee, will moderate the series. This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

Upcoming Webinars

Title Presenter

Immunotherapy of Lung Cancer –CME Activity Julie Brahmer

Management of Patients with ALK Positive NSCLC –CME Activity Alice Shaw

Surgical Approach to NSCLC – What is new – CME Activity David Harpole

Advanced Squamous Cell Lung Cancer – CME Activity Giorgio Scagliotti

Tissue Acquisition and Processing for Molecular Testing –CME Activity To be announced

Grand Rounds Series 6-14 –CME Activity To be announced

Complimentary to this was the continued progress toward the IASLC e-library, which will include all future textbooks, atlases, handbooks, manuals, posters and meeting materials. Eventually all educational materials will be incorporated into the e-library and will be searchable and available on the IASLC website.

11

IASLC in 2013

Publications

Journal of Thoracic Oncology (JTO), the official journal of the IASLC, continues to be a leading educational and informational periodical for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. JTO emphasizes a multidisciplinary approach, and includes original research (basic, clinical and translational), reviews, and opinion articles. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology. In 2013 there were 1301 articles submitted and 244 were published, equating to an acceptance rate of 19%. The turn-around time for the first post-submission decision was in average 14 days. There were 165,098 full text views and 214,853 website visits in 2013. The JTO was ranked 42 out of 196 for oncology and 6 out of 52 for respiratory system subject matter categories in the 2012 Journal Citation Reports and had an impact factor of 4.473. Dr. Alex Adjei was selected from an international pool of candidates to replace Dr. James Jett and become the second Editior-in-Chief of the JTO with his editorship commencing in January 2013. Dr. Adjei updated the editorial board in order to align with specialties such as genomics, genetic epidemiology, quality of life, symptom control, survivorship, outcomes research, health economics, and public policy. The new editorial board still represents the multidisciplinary nature of thoracic oncology as well as the large international membership of IASLC.

July 2013 saw the culmination of a tremendous amount of time and effort to construct a new website for the organization. This work was overseen and directed by the Communications Committee and IASLC staff. Additionally with the new website came a new and improved format for the monthly IASLC newsletter. The Editor of the newly

12

IASLC in 2013

formatted newsletter is the Chair of the Communications Committee and in addition to being e-mailed to all members it is now available online. The newsletter contains the President’s Corner, Chief Executive Officer’s Corner, News, Upcoming Events and Deadlines, and Special Features.

In the development of personalized therapy for patients with lung cancer, the IASLC, the College of American Pathologists (CAP), and the Association for Molecular Pathology (AMP) developed an evidence-based guideline, Molecular Testing Guideline for the Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors, which establishes standards for EGFR and ALK testing, helping to guide targeted therapies. The guideline was released electronically in April 2013 in the Journal of Thoracic Oncology, Archives of Pathology & Laboratory Medicine, and the Journal of Molecular Diagnostics and in print in July 2013. The guideline has become a globally recognized reference for molecular testing in lung cancer.

During 2013 the IASLC developed its own publishing imprint, the IASLC press, which published in October of the IASLC Atlas of ALK Testing in Lung Cancer, which is designed to help pathologists, laboratory scientists, and practicing physicians better understand the background and protocols for various methods of ALK testing and aid in the interpretation of test results for patients with advanced NSCLC. The publication was the culmination of collaboration by many internationally recognized and dedicated IASLC members and edited by Drs. Ming S. Tsao, Fred R. Hirsch, and Yasushi Yatabe. The initial printing of 10,000 copies

IASLC Newsletter

13

IASLC in 2013

has been distributed to clinicians and scientists around the world and Android and iOS mobile apps are now available. The process has started for translation of the IASLC Atlas of ALK Testing in Lung Cancer into Chinese, Japanese and Spanish, which will be available in 2014.

The celebration of IASLC’s 40 year anniversary kicked off in 2013 and will continue through the WCLC in 2015. In recognition of this monumental occasion, Celebrating 40 years, 1974-2013, of the IASLC and Research Advancements, a print monograph on the Progress in Lung Cancer was created through the vision and tireless efforts of Dr. Paul A. Bunn, Jr, the IASLC Board of Directors and numerous dedicated volunteers. The monograph chronicled the most significant and impactful research that advanced progress in lung cancer for each decade as well as highlighting the accomplishments and programs of the IASLC that communicated these advances to the international community of lung cancer experts.

Work continued in 2013 for the IASLC Multidisciplinary Approach to Thoracic Oncology textbook, which will include Lung Control and Epidemiology, Molecular Carcinogenesis, Pathology, Clinical and Radiologic Presentation, Diagnosis and Staging, Surgical Management, Radiotherapeutic Management, Chemotherapy and Targeted Agents, Other Thoracic Malignancies, Symptom Management and Complications, Clinical Trials, and Thoracic Oncology Advocacy. The textbook will include contributions from 150

international experts and is under the direction of Executive Editor Dr. Harvey I. Pass and Editors Drs. David Ball and Giorgio V. Scagliotti. The textbook is scheduled for completion in May 2014 and will be available in print and digital versions. A chapter reprint from the textbook, Gender-Related Differences in Lung Cancer by Drs. Silvia Novello, Laura P. Stabile, and Jill M. Siegfried, was distributed to the 6,000 attendees of the 2013 WCLC.

The IASLC published in partnership with Patient Resource the 3rd edition of the Patient Resource Cancer Guide for Lung Cancer; Where Information Equals Hope. This guide provides lung cancer patients

14

IASLC in 2013

and their loved ones with the details they need upon diagnosis and includes details regarding treatment options, staging, and symptom and side-effect management as well as the many advocacy and financial resources available.

Work continued in 2013 for the International Thymic Malignancies Interest Group (ITMIG) and IASLC who have partnered in a formal, structured process to develop a well-defined stage classification system for the next (eighth) edition of the stage classification. This involves an international committee of experts, creation of a large (by thymic standards) database, and careful analysis of data regarding multiple aspects that influence the definition of stage descriptors and grouping.

15

IASLC in 2013

Awards

The IASLC continued in 2013 its long tradition of award presentations for outstanding dedication and work in lung cancer and commitment to the organization. The IASLC merit award, which started in 1991, is given to a member who has made an extraordinary contribution to the organization’s development. Dr. James Jett was the 2013 recipient of the IASLC Merit Award for his many years of contribution to the IASLC, particularly as the first Editor-in-Chief of the Journal of Thoracic Oncology, the capacity he held for 8 years. Dr. Jett built up the journal to a highly recognized and well-established scientific periodical and resource virtually from scratch.

The IASLC Board of Directors declared in honor of the immense contributions and commitment of Dr. Paul A. Bunn, Jr. to the IASLC to rename the IASLC Scientific Award the Paul A. Bunn, Jr. Scientific Award. The Paul A. Bunn, Jr. Scientific Award is given to an IASLC scientist for lifetime scientific contributions in thoracic malignancy research and who has also contributed to the organization's development. The first recipient of the 2013 Paul A. Bunn, Jr. Scientific Award was Dr. David Gandara for his many years of significant contribution to clinical and translational lung cancer research. Through his capacity as chairman for the Southwest Oncology Cooperative Group (SWOG) lung committee he has initiated numerous and highly noteworthy clinical studies including many studies with a translational component. Most recently Dr. Gandara has led the heroic effort to generate genetically specific mouse models from transplanted patient tumors thus creating model systems that can explore new targeted-therapies and combinations.

The Mary J. Matthews Award is given to an IASLC scientist for lifetime scientific achievements in pathology-translational research of thoracic malignancies. Dr. Matthews was a Senior Investigator and Pathologist at the National Cancer Institute (NCI) Medical Oncology Branch and a pioneer in the foundation of the histological subtypes of lung cancer and the relationship between those subtypes and the clinical course of lung cancer. She focused on morphological heterogeneity of lung cancer and was the first to recognize that SCLC was disseminated at the time of diagnosis, leading to distinctions between SCLC and NSCLC. Dr. Tetsuya Mitsudomi was awarded the 2013 Mary J. Matthews award for his clinical and translational research where he has, as a surgeon, contributed for many years to the molecular characterization of lung cancer. Dr. Mitsudomi has particularly focused on EGFR inhibitors and the importance of EGFR mutations.

The Joseph W. Cullen Award is given to an IASLC scientist for lifetime scientific achievements in prevention research of thoracic malignancies. Dr. Cullen served as the Deputy Director of the NCI

Paul A. Bunn, Jr

Mary J. Matthews

16

IASLC in 2013

Division of Cancer Prevention and Control. He created the Smoking Tobacco and Cancer Program (STCP) at the NCI in 1982 and one of the major achievements of the STCP was the establishment of the American Stop Smoking Intervention Study for Cancer Prevention, widely known as ASSIST, which represented a major shift in federal funding for tobacco control from a primary focus on individuals to include a focus on the community and social environment. Dr. Pieter Postmus was with recipient of the Joseph Cullen Prevention/Early Detection Award in 2013 for his many years of contribution to the lung cancer community, particularly his work in early detection of lung cancer. Dr. Postmus, as a pulmonologist, has for numerous years developed a world-renowned lung cancer group and program in Amsterdam. Key research studies focusing on preneoplastic changes, which can lead to lung cancer, have been conducted under his leadership.

2013 Awards:

At the 2013 WCLC there were 10 Conference Fellowship Awards, 10 Developing Nations Awards and 5 advocacy awards presented.

Conference Fellowship Awards

Recipient Institution Country

Kathryn Ann Gold MD Anderson Cancer Center USA

Vinai Gondi Cadence Brain Tumor Center USA

Jill Everland Larsen Queensland Institute of Medical Research Australia

Dr. James Jett USA

Paul A. Bunn, Jr. Scientific Award

Mary J. Matthews Pathology/Translational

Research Award

Joseph W. Cullen Prevention/Early Detection Award

IASLC Merit Award

Dr. David Gandara USA

Dr. Tetsuya Mitsudomi Japan

Dr. Pieter Postmus The Netherlands

Joseph W. Cullen

17

IASLC in 2013

Yu Liu Cancer Institute (Hospital), Peking Union Medical College & Chinese Academy of Medical Sciences China

Tatsuo Maeyashiki Juntendo University School of Medicine Japan

Victor Daniel Martinez Zamora BC Cancer Research Centre Canada

Geoffey R. Oxnard Dana-Farber Cancer Institute USA

Tai Sun Park Asan Medical Center Korea

Jessica C. Sieren University of Iowa USA

Anish Thomas National Cancer Institute USA

Developing Nations Awards

Recipient Institution Country

Ning Cheng Lanzhou University China

Neekkan Dey University of Calcutta India

Alexander Kabakov Medical Radiology Research Center Russia

Urvashi Kaushik Public Health Foundation of India India

Natalia Khranovska National Cancer Institute MPH of Ukraine Ikraine

Yubo Liu, Dalian University of Technology China

Conjeevaram. Pramesh Tata Memorial Centre India

Subrata Saha Apollo Gleneagles Hospitals India

Cinthya Sternberg Brazilian National Cancer Institute Brazil

Natthaya Triphuridet Chulabhorn Hospital Thailand

Advocacy Awards

Recipient Organization Country

Trinidad Donoso Clínica Santa María Chile

Melinda Kotzian Mesothelioma Applied Research Foundation United States

Merel Nissenberg Mountain Clifton F. Mountain Foundation United States

Beth Stern Lung Cancer Foundation of America United States

Robert Vojakovic Asbestos Diseases Society of Australia, Inc. Australia

18

IASLC in 2013

Meetings

The IASLC has expanded its number of CME accredited programs in 2013 after becoming a CME provider accredited by the ACCME in December of 2012. In October 2013 the 15th World Conference on Lung Cancer convened in Sydney Australia with a record number of abstracts, 2316, submitted. The WCLC had 5,324 delegates from a multitude of disciplines attending from 93 countries and participating in 160 sessions. The sessions included presentations from numerous core programs including biology, prevention/epidemiology, pulmonary/endoscopy, imaging and screening, combined modality, medical oncology, mesothelioma, radiation oncology, surgery, pathology, nurses, supportive care, and statistics. Implemented in 2013 was the Best of WCLC, which is an educational initiative of IASLC designed to engage researchers and practitioners unable to attend the WCLC. The program condenses the timeliest scientific and educational topics from multiple disciplines into a 1-2 day event and held at 17 locations around the globe in 2013-14. The chairs for the individual meeting received the power points from all oral presentations and they could make their own agenda and focus on the areas that meet their specific needs.

Best of WCLC 2013

Location Date Organizer/Chair Number of Attendees

Milan, Italy November 7, 2013 Federico Cappuzzo 200

Salvador, Bahia, Brazil November 29-30, 2013 Brazilian Group of Thoracic Oncology 200

Guangzhou, China November 30, 2013 Yi-Long Wu 400

Tokyo, Japan November 2013 Hisao Asamura 272

Dresden, Germany December 5-6, 2013 Christian. Manegold 125

Seoul, Korea December 7, 2013 Keunchil. Park 325

Paris, France December 6, 2013 Thierry LeChevalier 205

Copenhagen, Denmark December 13, 2013 Peter Meldgaard 100

San Francisco, CA December 2013 Karen Kelly 125

New York, NY January 18, 2014 H. Pass J. Donington 40

Athens, Greece February 28-March 1, 2014 V. Georgoulias

Cordoba, Argentina March 2014 E. Richardet

Hyderabad, India March 2014 Sai Yendamuri Alex Adjei

19

IASLC in 2013

Porto Alegre, Brazil March 2014 G. Schwartzman

Dallas, TX May 2, 2014 K. Kernstine

Mexico City May 15-17, 2014 Oscar Arrieta

Tel Aviv, Israel May 15, 2014 Nir Peled

February 2013 saw the 13th Annual Targeted Therapies of the Treatment of Lung Cancer in Santa Monica, USA. This invitation only meeting attended by 400 participants offers a unique format to present and discuss data on novel targets, drug development for new and established targets, biomarkers, and clinical trial design. This meeting affords the opportunity for members of academia, government, and industry to interact and includes clinicians, basic scientists, regulatory officials, and industry executives.

IASLC endorsed a number of meetings during 2013.

Meetings Endorsed and Supported by IASLC 2013

Name of meeting Location Date

British Thoracic Oncology (BTOG) Dublin, Ireland January, 2013

MD Anderson Cancer Center Madrid Lung Cancer meeting Madrid, Spain February, 2013

6th IASLC International conference on Molecular Targeted Therapy in Lung Cancer Sorrento, Italy April, 2013

European Society of Thoracic Surgeons (ESTS) Birmingham, UK May, 2013

High Resolution CT Imaging Workshop Bethesda, Maryland, US May, 2013

14th International Lung Cancer Congress Huntington Beach, California, USA July, 2013

ITMIG meeting Bethesda, Maryland, USA September, 2013

6th Annual Symposia on Personalized and Best Clinical Practices for Lung Cancer Los Angeles, California, USA November, 2013

10th Congress on Lung Cancer Barcelona, Spain November, 2013

The International Best of WCLC 2013 presentations will continue into 2014 and there are a multitude of other meetings and events planned in 2014 and beyond.

20

IASLC in 2013

Upcoming Meetings and Events

Name of meeting Location Date Chairs/Organizers

Molecular Origins of Lung Cancer San Diego, USA January 6-9, 2014

Roy Herbst Elisabeth Brambilla Pasi Janne William Pao

14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting

Santa Monica, USA

February 19-22, 2014

Paul A. Bunn, Jr. David H. Johnson Roy Herbst

European Lung Cancer Conference (ELCC) Geneva, Switzerland

March 26-29, 2014

Rafal Dziadziuszko Enriqueta Felip

Latin American Lung Cancer Conference (LALCA) Lima, Peru August 21-23,

2014 Carlos Vallejos Sologuren

Chicago Multidisciplinary Symposium in Thoracic Oncology Chicago, USA

October 30 - November 1, 2014

Members of IASLC, ASCO, ASTRO, and University of Chicago

Asian Pacific Lung Cancer Conference Kuala Lumpur, Malaysia

November 6-8, 2014

Chong-Kin Liam Mohamed Ibrahim A. Wahid

16th World Conference on Lung Cancer Denver, USA September 6-10, 2015 Fred R. Hirsch

17th World Conference on Lung Cancer Vienna, Austria December 4-7, 2016 Robert Pirker

18th World Conference on Lung Cancer Yokohama, Japan November 2017 To be announced

19th World Conference on Lung Cancer Toronto, Canada November 2018 To be announced

21

IASLC in 2013

Strategic Plan

The mission of the IASLC is

• to embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies

• to provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public

• to use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.

The IASLC Board of Directors approved a new strategic plan for the organization on September 12, 2011. This ambitious plan was developed after a 6-month process that culminated in a Strategic Planning Retreat, September, 2011 in Denver, USA. During 2012 the staff identified numerous action items required to make significant steps toward achieving the plan. In 2013 a wealth of activities to support the plan were undertaken by various IASLC constituents, a summary is provided below.

Mission

GOAL 1 - IASLC embraces the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.

• The IASLC Staging Committee made significant progress in its multi-year effort to update the International Staging Classification for Lung Cancer. With new classifications in Mesothelioma and Thymic malignancies the new classifications scheduled for 2015 publication will be the most comprehensive ever.

• The IASLC Pathology Committee continued its work toward development of a new WHO/IASLC classification (planned completion 2015) as well as providing educational information to the field such as the new IASLC Atlas of ALK Testing in Lung Cancer.

• The newly formed IASLC Tobacco Control and Smoking Cessation Committee was actively involved in providing support to exclude tobacco products from trade agreements, promoting plain packing initiatives and encouraging smoking cessation programs for practitioners.

• IASLC continued its work to improve diagnosis of lung cancer through better screening protocols. The IASLC Prevention, Screening and Early Detection Committee brought together experts from numerous organizations and agencies to share information and identify ways to support recommendations across-borders.

Education

GOAL 2 - IASLC provides education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.

22

IASLC in 2013

• IASLC was granted provisional status in 2012 by the AACME. During 2013 IASLC launched its first CME enhanced webinars and granted delegates at the WCLC CME credits upon request.

• IASLC continued to build its educational webinars with Personalized Therapy. Immunotherapy, Advanced Radiation Therapy and the jointly produced Molecular Testing webinar in conjunction with the College of American Pathologist and The Association for Molecular Pathology

• IASLC implemented the new annual World Conference on Lung Cancer format by selecting Yokohama, Japan for the 2017 WCLC and Toronto, Canada for the 2018 WCLC to follow Denver, USA in 2015 and Vienna, Austria in 2016.

• The 2013 WCLC in Sydney, Australia included nearly 5,500 participants, a record attendance for conferences in the Asia Pacific region. A record number of abstracts supported the scientific presentations at the conference and delegates were treated to Australian hospitality, information from top companies in the industry and an opportunity to collaborate with colleagues from around the world.

• IASLC introduced the first phase of an enhanced website providing for more content to be distributed to members and the public. Initial results show a 92% increase in average visits to the site, a 165% increase in pages visits, average duration on the site up 52% and a 16.5% reduction in the bounce rate for visitors. Additional content development is underway.

• IASLC introduced the first official series of the “Best of WCLC” and with the help of local experts provided the most significant updates from the WCLC to hundreds of participants in nine international locations unable to attend the WCLC in 2013 and an additional 8 sites are planned for early 2014.

• IASLC concluded a year-long research project documenting the progress in research into all aspects of lung cancer and thoracic malignancies since its founding in 1974. This project cumulated in a monograph provided to all delegates at the WCLC in Sydney and multiple displays at the conference. The monograph is available for downloading on the IASLC website where a historical timeline also provides a walk thorough of historical developments.

Research and Science

GOAL 3—IASLC advances research and science towards reducing the burden of thoracic malignancies worldwide.

• IASLC continues its funding of fellowships to promote scientific excellence and to encourage innovative research. During the year IASLC supported seven fellows in it two-year program, began a new Chinese fellowship and began support of a new prestigious Lung Cancer Foundation/IACLC fellow.

• The IASLC Journal of Thoracic Oncology continued to expand its coverage of the top translational and basic research and added significantly to its subscriber base.

23

IASLC in 2013

• The JTO Editorship successfully transferred from Dr. James Jett, MD to Dr. Alex Adjei, MD at the beginning of the year.

• IASLC hosted the 13th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting bringing together a sold-out group of participants to this invitation only gathering of the top practitioners, scientists and industry experts.

Organizational Growth

GOAL 4 - IASLC is committed to long-term, global growth in membership.

• As noted elsewhere IALSC continues its long term growth having increased membership by 20% during 2013 while expanding the diversity of its members across the world and across specialties.

• During 2013 IASLC launched a new membership database to allow for detailed tracking of membership demographics and participation. The new system reduces the cost of managing growth both by fixing annual expenses and creating data entry efficiencies.

• Through the membership system IASLC is able to track the 20,000 individual touched by the membership and education programs in 2012 and 2013 to support future growth.

Professional Membership Association

GOAL 5 - IASLC values the work of its volunteer members, who advance the IASLC mission through active participation and effective leadership.

• The evolution in new educational opportunities and growth in membership is a direct result of the hard work of IASLC members who volunteer their time and expertise to raise the standards of our work and seek new members to join the association.

• During the year IASLC engaged nearly twice as many committees and committee members to support programs and membership initiatives for new specialties extend the geographic reach of IASLC and to support new initiatives in tobacco control and smoking cessation, patient-physician materials and advocacy.

Charitable Giving and Philanthropic Relationships

GOAL 6 - IASLC solicits philanthropic funds to support its research and educational programs.

• IASLC created a charitable foundation in 2013 and is now in the planning process of developing donor programs to launch in late 2014.

• During 2013 IASLC initiated modest programs for members and speakers to contribute to the fellowship program. These programs continue in2014 and set the stage for enhanced programs in the coming years under the IASLC Foundation umbrella.

24

IASLC in 2013

• Fellowship grants received during the year achieved one of the top level since the program was initiated.

Operational Soundness

GOAL 7 - To accomplish its mission, the IASLC is committed to operational excellence and fiscal responsibility.

• During 2013 IASLC diversified its revenue streams by increasing the sources of support for educational programs such as webinars, creating new publications and digital applications and adjusting the format of the WCLC to dramatically decrease costs.

• During the year the new membership database contributed to reduced membership fulfillment costs in excess of $70,000, reduced IT and staffing costs through operational efficiencies, contributed to improved accounting while increasing opportunities for enhance membership programs in the coming years

• IASLC’s operating results are expected to close near the budget despite unfavorable swings in the Australian Dollar used at the Sydney WCLC and net surpluses are expected to be positive.

25

IASLC in 2013

Advocacy Partners and Sponsors

In 2013, IASLC continued its working relationship with many advocacy organizations around the world. These advocacy partners are conducting critical work in the areas of patient education and support, public awareness, fundraising, government lobbying, clinical trials enrollment, among many other important activities. IASLC applauds the achievements and support of these groups

2013 Advocacy Partners

Bonnie J. Addario Lung Cancer Foundation Dusty Joy Foundation EX - A new way to think

about quitting smoking Free Me From Lung Cancer

Global Lung Cancer Coalition

Global Resource for Advancing Cancer Education (GRACE)

International Thoracic Oncology Nursing Forum Lung Cancer Alliance

Lung Cancer Foundation of America (LCFA) Lungevity Foundation Mesothelioma Applied

Research Foundation My Cancer Genome

Free to Breathe (formely) National Lung Cancer Partnership

Prevent Cancer Foundation Union for International Cancer Uniting Against Lung Cancer

Women Against Lung Cancerin Europe

In order to accomplish the mission of the IASLC a tremendous amount of time, effort and dedication is required by numerous people as well as support from many sponsors. The IASLC would like to thank the 2013 sponsors who once again assisted the society in being the world-renowned organization that it is.

2013 Sponsors

Abbott Oncology Accuray, Inc. Amgen Astellas Pharma

Astex AstraZeneca Bayer HealthCare Bio Connections, LLC

Biodesix, Inc. BioOncology Biothera Bristol-Myers Squibb

Boehringer Ingelheim Caris Life Science Celgene Clovis Oncology

Daiichi Sankyo Elekta Eli Lilly and Company Genentech/Roche

Gilead Sciences, Inc. Global Resource for Advancing Cancer Education (GRACE)

GlaxoSmithKline GTx

ImmunoGen, Inc. Janssen Pharmaceuticals, Inc. Johnson & Johnson Life Technologies

26

IASLC in 2013

Lung Cancer Foundation of America (LCFA) MedImmune Merck Myriad Genetics, Inc.

Novartis Peregrine Pharma Pfizer Oncology Puma Biotechnology, Inc.

Qiagen Roche Synta Pharmaceuticals TEVA Pharmaceuticals

Varian Ventana/Roche

Future Plans

Despite the many IASLC achievements obtained in 2013, many challenges remain to be addressed within screening, early detection and treatment of lung cancer. We have witnessed over the last year significant progress and IASLC is committed to facilitate scientific advancements nationally and internationally in order to conquer thoracic malignancies. Emerging information and technology requires continuous diligence to distribute information and education globally. It is our hope that 2014 will bring new advancements in treatment and care of patients with thoracic malignancies and IASLC will put special emphasis to also reach out to community practices, nurses and other allied health care professionals as well as to patient advocates. Increased interaction with other disciplines and organizations is vital to achieve our common goals; to improve the care and life expectancies of patients with thoracic malignancies and ultimately reduce mortality.

27